Study Sites

The A-TANGO consortium performs Phase 2 clinical studies of an innovative therapeutic strategy that improves hepatocyte proliferation through granulocyte colony-stimulating factor (G-CSF) and reduces systemic inflammation by repurposing TAK-242, an antagonist of toll-like receptor 4 (TLR4). We call this novel combinatorial therapy “G-TAK”. Up to 30 liver centres in Europe will participate in the clinical study, which is supervised by Dr. Cornelius Engelmann (Charité), while Prof. Dr. Rajiv Jalan (EFCLIF and UCL), a highly experienced and accomplished hepatologist coordinates the scientific progress of the entire A-TANGO project.

To find out the address of the closest liver centre that participates in the clinical study of A-TANGO and how to contact the principal investigator (the local hepatologist in charge), please select your country.